全文获取类型
收费全文 | 2215篇 |
免费 | 120篇 |
国内免费 | 14篇 |
学科分类
医药卫生 | 2349篇 |
出版年
2023年 | 18篇 |
2022年 | 52篇 |
2021年 | 75篇 |
2020年 | 37篇 |
2019年 | 52篇 |
2018年 | 72篇 |
2017年 | 35篇 |
2016年 | 53篇 |
2015年 | 76篇 |
2014年 | 76篇 |
2013年 | 84篇 |
2012年 | 160篇 |
2011年 | 139篇 |
2010年 | 91篇 |
2009年 | 95篇 |
2008年 | 126篇 |
2007年 | 146篇 |
2006年 | 93篇 |
2005年 | 80篇 |
2004年 | 87篇 |
2003年 | 87篇 |
2002年 | 73篇 |
2001年 | 43篇 |
2000年 | 50篇 |
1999年 | 42篇 |
1998年 | 21篇 |
1997年 | 24篇 |
1996年 | 26篇 |
1995年 | 12篇 |
1994年 | 12篇 |
1993年 | 14篇 |
1992年 | 37篇 |
1991年 | 23篇 |
1990年 | 19篇 |
1989年 | 14篇 |
1988年 | 17篇 |
1987年 | 14篇 |
1986年 | 12篇 |
1985年 | 16篇 |
1984年 | 14篇 |
1983年 | 12篇 |
1982年 | 9篇 |
1981年 | 7篇 |
1980年 | 12篇 |
1979年 | 7篇 |
1975年 | 8篇 |
1974年 | 7篇 |
1972年 | 12篇 |
1971年 | 6篇 |
1966年 | 5篇 |
排序方式: 共有2349条查询结果,搜索用时 15 毫秒
71.
72.
73.
Gopal AK Gooley TA Maloney DG Petersdorf SH Eary JF Rajendran JG Bush SA Durack LD Golden J Martin PJ Matthews DC Appelbaum FR Bernstein ID Press OW 《Blood》2003,102(7):2351-2357
We performed a multivariable comparison of 125 consecutive patients with follicular lymphoma (FL) treated at our centers with either high-dose radioimmunotherapy (HD-RIT) using 131I-anti-CD20 (n = 27) or conventional high-dose therapy (C-HDT) (n = 98) and autologous hematopoietic stem cell transplantation. The groups were similar, although more patients treated with HD-RIT had an elevated pretransplantation level of lactate dehydrogenase (41% versus 20%, P =.03) and elevated international prognostic score (41% versus 19%, P =.02). Patients treated with HD-RIT received individualized therapeutic doses of 131I-tositumomab (median, 19.7 GBq [531 mCi]) to deliver 17 to 31 Gy (median, 27 Gy) to critical organs. Patients treated with C-HDT received total body irradiation plus chemotherapy (70%) or chemotherapy alone (30%). Patients treated with HD-RIT experienced improved overall survival (OS) (unadjusted hazard ratio [HR] for death = 0.4 [95% confidence interval (95% CI), 0.2-0.9], P =.02; adjusted HR, 0.3, P =.004) and progression-free survival (PFS) (unadjusted HR =.6 [95% C.I., 0.3-1.0], P =.06; adjusted HR, 0.5, P =.03) versus patients treated with C-HDT. The estimated 5-year OS and PFS were 67% and 48%, respectively, for HD-RIT and 53% and 29%, respectively, for C-HDT. One hundred-day treatment-related mortality was 3.7% in the HD-RIT group and 11% in the C-HDT group. The probability of secondary myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) was estimated to be.076 at 8 years in the HD-RIT group and.086 at 7 years in the C-HDT group. HD-RIT may improve outcomes versus C-HDT in patients with relapsed FL. 相似文献
74.
75.
Stephen D. Smith Brian G. Till Mazyar S. Shadman Ryan C. Lynch Andrew J. Cowan Qian V. Wu Jenna Voutsinas Heather A. Rasmussen Katherine Blue Chaitra S. Ujjani Andrei Shustov Ryan D. Cassaday Jonathan R. Fromm Ajay K. Gopal 《British journal of haematology》2020,189(6):1119-1126
Tumor programmed death-ligand 1 (PD-L1) expression in diffuse large B-cell lymphoma (DLBCL) is associated with inferior outcomes. The first-line immunologically-replete setting may be an opportune time for PD-1 inhibition. We evaluated pembrolizumab in combination with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) in untreated patients with DLBCL. Eligible patients were age 18 or older, had adequate organ function, and had DLBCL requiring full-course therapy. Patients received pembrolizumab 200 mg/cycle with R-CHOP, primarily to assess toxicity. Response assessment utilized standard criteria, and PD-L1 staining was performed at a validated central laboratory. Among 30 patients, toxicity was comparable to standard R-CHOP but with two grade ≥3 immune related adverse events (rash, pneumonitis). The overall and complete response rate was 90% and 77%. With 25·5 months of median follow-up, 2-year progression-free survival (PFS) is 83%. PD-L1 expression was associated with non-GCB subtype, and improved PFS and survival. Pembrolizumab can safely be added to R-CHOP, and is associated with a high CR rate and 2-year PFS. Improved PFS with PR-CHOP in PD-L1 expressing tumors contradicts historical data in R-CHOP treated patients, supporting evaluation of PD-L1 as a biomarker to identify DLBCL patients who may benefit from this first-line strategy. 相似文献
76.
Victor A. Chow MD Joseph G. Rajendran MD Darrell R. Fisher Frederick R. Appelbaum MD Ryan D. Cassaday MD Paul S. Martin MD Leona A. Holmberg MD PhD Theodore A. Gooley PhD Philip A. Stevenson MS John M. Pagel MD PhD Damian J. Green MD Oliver W. Press MD PhD Ajay K. Gopal MD 《American journal of hematology》2020,95(7):775-783
Radiation is the most effective treatment for localized lymphoma, but treatment of multifocal disease is limited by toxicity. Radioimmunotherapy (RIT) delivers tumoricidal radiation to multifocal sites, further augmenting response by dose-escalation. This phase II trial evaluated high-dose RIT and chemotherapy prior to autologous stem-cell transplant (ASCT) for high-risk, relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (NHL). The primary endpoint was progression free survival (PFS). Secondary endpoints were overall survival (OS), toxicity, and tolerability. Patients age < 60 years with R/R NHL expressing CD20 were eligible. Mantle cell lymphoma (MCL) patients could proceed to transplant in first remission. Patients received I-131-tositumomab delivered at ≤25Gy to critical normal organs, followed by etoposide, cyclophosphamide and ASCT. A group of 107 patients were treated including aggressive lymphoma (N = 29), indolent lymphoma (N = 45), and MCL (N = 33). After a median follow-up of 10.1 years, the 10-year PFS for the aggressive, indolent, and MCL groups were 62%, 64%, 43% respectively. The 10-year OS for the aggressive, indolent, and MCL groups were 61%, 71%, 48% respectively. Toxicities were similar to standard conditioning regimens and non-relapse mortality at 100 days was 2.8%. Late myeloid malignancies were seen in 6% of patients. High-dose I-131-tositumomab, etoposide and cyclophosphamide followed by ASCT appeared feasible, safe, and effective in treating NHL, with estimated PFS at 10-years of 43%-64%. In light of novel cellular therapies for R/R NHL, high-dose RIT-containing regimens yield comparable efficacy and safety and could be prospectively compared. 相似文献
77.
Abdelbasset Walid Kamal Alrawaili Saud M. Nambi Gopal Yassen Eman Moawd Samah A. Ahmed Ahmed S. 《Clinical rheumatology》2020,39(10):3091-3097
Clinical Rheumatology - Diabetic neuropathy (DN) is a common and serious complication of diabetes. DN patients are suffering from anxiety, depression, and impairment of functional capacity. Rare... 相似文献
78.
Waheed Anem Fongemie Justin Gopal Srila Esham Kimberly S. Richardson-Weber Leslie Zhang Lulu Van Doren Layla Buchsbaum Rachel J. Comenzo Raymond L. 《Journal of thrombosis and thrombolysis》2020,50(3):715-717
Journal of Thrombosis and Thrombolysis - 相似文献
79.
P. R. Venu Gopal P. Kumar George K. George Naveen Hood Lidiya James Milthi Manoj Joseph Francis 《The Indian journal of surgery》2014,76(5):378-381
The rare situation of thyroid stone is discussed with literature review and case report. A case of isolated solitary stone of the thyroid is documented here. There are incidences of calcification in the thyroid gland commonly associated with carcinoma thyroid and multinodular goiter. But solitary stone of thyroid is reported rarely and one such case is reported from India. The possibility of malignancy is high, in case of calcification of thyroid swellings. Hence, isolated calcification should be surgically treated even if fine needle aspiration cytology is negative for malignancy. 相似文献
80.
Aruna V. Vanikar Hargovind L. Trivedi Saroj Chooramani Gopal Ashutosh Kumar Shruti D. Dave 《Renal failure》2014,36(3):457-460
Transplantation tolerance is still a Utopian dream for many transplanters. Mesenchymal stem cells (MSC) have shown immuno-modulatory and tolerogenic effects in experimental models. We present a 29-year-old male with end stage renal disease (ESRD) who was transplanted with HLA 4/6 matched kidney from 51-year-old father in June 2010 preceded by co-infusion of donor-adipose tissue derived mesenchymal stem cells (AD-MSC) and bone marrow derived hematopoietic stem cells (BM-HSC) under non-myeloablative conditioning for deleting rejecting T and B-cells. He has maintained fairly stable graft function with serum creatinine (SCr) between 1.5 and 1.8?mg/dL at 3 years post-transplant with absence of donor specific antibodies (DSA), normal protocol graft biopsy, and peripheral T-regulatory cell levels (pTregs) (CD127low/?CD25highCD4+) of 4.57% on zero immunosuppression since 6 months. 相似文献